Patent Assignment
Reel/Frame 045417/0593
Corrective Assignment to Correct the Us Patent No. 8,050,873 Previously Recorded on Reel 040183 Frame 0129. Assignor(S) Hereby Confirms the Assignment.
Recorded: 2018-02-22
Pages: 16
Assignor
WARNER CHILCOTT COMPANY, LLC
Executed: 2015-12-31
Assignee
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
CLONSHAUGH INDUSTRIAL ESTATE, COOLOCK, DUBLIN 17, IRELAND
Covered Properties
(86)
Crystalline Salts of (4S,4AS,5AR,12AS)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide and Methods of Using the Same
5-Aminosalicylic Acid Capsule Formulation
Compositions Comprising 5-Amino-2-Hydroxybenzoic Acid and a Reducing Sugar
Application:
12/769,293 →
Publication:
US US20100210605A1
Estrogen compositions for vaginal administration
Gel compositions for topical administration
Application:
11/454,717 →
Publication:
US US20060292223A1
Intravaginal drug delivery devices
Application:
10/564,031 →
Publication:
US US20070043332A1
Intravaginal Matrix Drug Delivery Devices
Low-Dose Estradiol Cream
Application:
14/645,512 →
Publication:
US US20150258117A1
Mesalamine Pharmaceutical Composition with Multiple Dosage Elements for Reduced Delivery Variability
Application:
61/794,998 →
Method for Improving Compliance with a Treatment Regimen for Treating or Preventing Osteoporosis
Application:
13/325,170 →
Publication:
US US20120145588A1
Methods of Using (4S,4AS,5AR,12AS)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide
Application:
13/893,717 →
Publication:
US US20130302442A1
Methods to Administer Solid Dosage Forms of Ethinyl Estradiol and Prodrugs Thereof with Improved Bioavailability
Application:
11/955,072 →
Publication:
US US20080113953A1
Pharmaceutical combinations
Application:
11/977,137 →
Pharmaceutical Combinations
Application:
12/868,021 →
Mesalamine Pharmaceutical Composition with Multiple Dosage Elements for Reduced Delivery Variability
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
Application:
11/096,457 →
Publication:
US US20050181053A1
Pharmaceutical Soft Gelatin Capsule Dosage Form
Application:
14/210,630 →
Publication:
US US20140271837A1
Pharmaceutical Soft Gelatin Capsule Dosage Form
Application:
61/794,813 →
Pharmaceutical Soft Gelatin Capsule Dosage Form with Modified Guar Gum
Pharmaceutical Soft Gelatin Capsule Dosage Form with Modified Guar Gum
Pharmaceutical Soft Gelatin Capsule Dosage Form with Modified Guar Gum
Application:
61/794,906 →
Bisphosphonate Compounds
Bisphosphonate Compounds
Bisphosphonate Compounds
Blister Card
Patent:
562,153 →
Application:
29/285,645 →
Chewable Oral Contraceptive
Patent:
6,667,050 →
Application:
09/879,028 →
Compositions of Azimilide Dihydrochloride
Coupling Process for Preparing Quinolone Intermediates
Derivative Prodrugs of Ethinyl Estradiol
Di-Steroidal Prodrugs of Estradiol
Di-Steroidal Prodrugs of Ethinyl Estradiol
Dosage Forms of Bisphosphonates
Dosage Forms of Bisphosphonates
Dosage Forms of Bisphosphonates
Dosage Forms of Risedronate
Doxycycline Metal Complex in a Solid Dosage Form
Doxycycline Metal Complex in a Solid Dosage Form
Extended Cycle Multiphasic Oral Contraceptive Method
Extended Cycle Multiphasic Oral Contraceptive Kit
Extended Cycle Multiphasic Oral Contraceptive Method
Extended Estrogen Dosing Contraceptive Regimen
Film-Coated Tablet for Improved Upper Gastrointestinal Tract Safety
Patent:
6,165,513 →
Application:
09/095,322 →
Film-Coated Tablet for Improved Upper Gastrointestinal Tract Safety
Patent:
6,569,460 →
Application:
09/694,799 →
Formulations and Methods of Treating Inflammatory Bowel Disease
Formulations and Methods of Treating Inflammatory Bowel Disease
Graduated Estrogen Contraceptive
Graduated Estrogen Contraceptive
Vitamin D Content Uniformity in Pharmaceutical Dosage Forms
Intravaginal Drug Delivery Devices for the Delivery of Macromolecules and Water-Soluble Drugs
Low Dosage Forms of Risedronate or Its Salts
Low Dosage Forms of Risedronate or Its Salts
Method of Enhancing Cognition
Patent:
5,837,724 →
Application:
08/872,891 →
Method of Treating Irritable Bowel Syndrome
Method of Treatment
Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
Methods for the Treatment of Osteoporosis
Patent:
6,329,354 →
Application:
08/008,859 →
Modified Release Formulations and Methods of Treating Inflammatory Bowel Disease
Oral Pharmaceutical Products Containing 17 Beta-Estradiol-3-Lower Alkanoate, Method of Administering the Same and Process of Preparation
Oral Pharmaceutical Products Containing 17BETA-Estradiol-3-Lower Alkanoate, Method of Administering the Same and Process of Preparation
Oral Pharmaceutical Products Containing 17BETA-Estradiol-3-Lower Alkanoate, Method of Administering the Same and Process of Preparation
Corticotropin Releasing Factor 2 Receptor Agonists
Corticotropin Releasing Factor 2 Receptor Agonists
Corticotropin Releasing Factor 2 Receptor Agonists
Corticotropin Releasing Factor 2 Receptor Agonists
Corticotropin Releasing Factor 2 Receptor Agonists
Corticotropin Releasing Factor 2 Receptor Agonists
Corticotropin Releasing Factor 2 Receptor Agonists
Pharmaceutical Combinations
Pharmaceutical Dosage Form with Multiple Coatings for Reduced Impact of Coating Fractures
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
Pharmaceutical Dosage Form with Multiple Coatings for Reduced Impact of Coating Fractures
Pharmaceutical Formulations Containing Darifenacin
Patent:
6,106,864 →
Application:
09/029,072 →
Process for Controlling Crystal Structure of Risedronate
Process for Making Geminal Bisphosphonates
Prostaglandin Compositions and Methods of Treatment for Male Erectile Dysfunction
Prostaglandin Compositions and Methods of Treatment for Male Erectile Dysfunction
Patent:
6,323,241 →
Application:
09/480,738 →
Prostaglandin Compositions and Methods of Treatment for Male Erectile Dysfunction
Pyrrolidine Derivatives
Patent:
5,233,053 →
Application:
07/800,191 →
Pyrrolidine Derivatives
Patent:
5,096,890 →
Application:
07/493,068 →
Quadraphasis Continuous Graduated Estrogen Contraceptive
Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
Stable Hydrate of a Muscarinic Receptor Antagonist
Stable Hydrate of a Muscarinic Receptor Antagonist
Topical Compositions
Patent:
6,841,161 →
Application:
09/423,715 →
Related Assignments
(23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 26, 2005
From: MULDOON, BRENDAN; LORIMER, COLIN; GILLIGAN, CLAIRE
To: GALEN (CHEMICALS) LIMITED
Reel/Frame 016194/0122 →
Change of Name
Jun 18, 2009
From: WARNER CHILCOTT COMPANY, INC.
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 022835/0896 →
Security Agreement
Nov 16, 2009
From: GALEN (CHEMICALS) LIMITED; PROCTER & GAMBLE PHARMACEUTICALS SARL
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023519/0430 →
Assignment of Assignor's Interest
Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →
Release - Reel 023519, Frame 0430
Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT (IRELAND) LIMITED (AS SUCCESSOR IN INTEREST TO GALEN CHEMICALS LIMITED); WARNER CHILCOTT PHARMACEUTICALS S.A.R.L. (SUCCESSOR IN INTEREST TO PROCTOR & GAMBLE PHARMACEUTICALS SARL
Reel/Frame 026042/0220 →
Release - Reel 023456, Frame 0052
Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
Security Agreement
Mar 30, 2011
From: WARNER CHILCOTT (IRELAND) LIMITED
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026065/0215 →
Change of Name
Jul 13, 2011
From: GALEN (CHEMICALS) LIMITED
To: WARNER CHILCOTT (IRELAND) LIMITED
Reel/Frame 026584/0948 →
Assignment of Assignor's Interest
Sep 25, 2012
From: COULTER, CATHERINE; JOHNSTON, SEAN M.; SEYEDI, FARZANEH
To: WARNER CHILCOTT COMPANY, LLC; PARATEK PHARMACEUTICALS, INC.
Reel/Frame 029018/0831 →
Release of Security Interest
Oct 9, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT (IRELAND) LIMITED
Reel/Frame 031394/0587 →
Release of Security Interest
Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
Security Interest
Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →
Release of Security Interest
Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
Termination of Lien on Patents
Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
Assignment of Assignor's Interest
Dec 21, 2015
From: MULDOON, BRENDAN; LOUGHLIN, RYAN GERALD; SWEENEY, GERARDE; BOYD, EMMA KAREN
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 037340/0031 →
Assignment of Assignor's Interest
Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →
Assignment of Assignor's Interest
Sep 29, 2016
From: WARNER CHILCOTT (IRELAND) LIMITED
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 039897/0584 →
Assignment of Assignor's Interest
Sep 27, 2021
From: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
To: ALLERGAN THERAPEUTICS LLC
Reel/Frame 057605/0461 →
Security Interest
Sep 22, 2023
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 065001/0917 →
Security Interest
May 22, 2025
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071200/0656 →
Release of Security Interest in Patents Recorded at Reel/Frame 065001/0917
May 22, 2025
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 071343/0407 →
Patent Security Agreement
Mar 16, 2026
From: PARATEK PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0244 →
Release of Security Interest in Patents Recorded at Reel/Frame 71200/0656
Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 075101/0815 →